ReachBio Research Labs
123 NW 36th Street
Suite 235
Seattle
Washington
98107
United States
Tel: 206-420-0300
Fax: 206-420-0301
Website: https://reachbio.com/
Email: info@reachbio.com
About ReachBio Research Labs
ReachBio Research Labs is a CRO life sciences organization based in Seattle, WA. It provides customized contract assays, contract research, educational and consulting services to pharmaceutical, biotechnology, and research organizations worldwide. The company’s focus is on the clinical, industrial and research uses of primary cell biology – in particular the use of stem cell and progenitor cell assays and model systems for high value applications such as drug screening and drug discovery.
YEAR FOUNDED:
2007
LEADERSHIP:
Founder and CSO: Emer Clarke
Founder and COO: Rob Chaney
PRODUCTS:
All Products
FOLLOW REACHBIO:
Tweets by ReachBio
5 articles about ReachBio Research Labs
-
Discovery Life Sciences Acquires Reachbio Research Labs
4/11/2023
Discovery Life Sciences™, the Biospecimen and Biomarker Specialists™, has acquired Seattle-based ReachBio Research Labs, a company specializing in cell-based assays, predictive hematotoxicity, and drug screening services.
-
A Platform for Screening Drugs To Treat Sickle Cell Disease Now Offered by ReachBio Research Labs
8/13/2019
ReachBio Research Labs (trade name under ReachBio LLC), a CRO specializing in primary cell assay services and products, is now offering a drug screening platform to assess HbF (fetal hemoglobin) protein induction in drug candidates to treat sickle cell disease as well as other hemoglobinopathies such as β-thalassemias.
-
ReachBio Research Labs Offers New Services for ADC Off-target Toxicity and Linker Stability
7/9/2019
ReachBio Research Labs, a CRO specializing in primary cell assay services and products, is now offering off-target toxicity and linker stability assay services for antibody drug conjugates.
-
ReachBio Research Labs Offers New NK (V158+) Cells Optimized For ADCC Assays Online
5/9/2017
-
ReachBio Research Labs Launches A New Drug Development Platform, cellPrism
1/31/2017